University Hospital, Angers

chu-angers.fr

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

469

Active

102

Phase 3

32

Total enrollment

504,221

Pipeline matrix

Showing 21 of 21 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
cyclosporine2
Nicotinamide1
Idarubicin1
Daunorubicin1
HD Cytarabine1
Methotrexate1
Mycophenolic acid1
vosaroxin1
ID cytarabine1
Dexamethasone1
Venetoclax1
Rivaroxaban 10 MG1
Low Heparin Molecular Weight1
Nicotinamide treatment1
Progressive (gradual) weaning of external ventricular drain1
Clonal architecture determination1
Continuous measurement of uPO21
Blood test1
Sulthiame1
Whole blood samples1
CALR allele burden quantification1

Next readouts

  • 2025-07
  • 2025-12-01
  • 2026-07-09
  • 2026-09
  • 2027-04-23
  • 2027-04-28
  • 2027-09-01
  • 2027-10-18
  • 2028-04
  • 2028-11-19

Top conditions

  • Peripheral Artery Disease11
  • Pseudoxanthoma Elasticum9
  • Pulmonary Embolism8
  • Peripheral Arterial Disease7
  • Septic Shock7
  • Healthy6
  • Thoracic Outlet Syndrome6
  • Acute Respiratory Distress Syndrome5

Frequently asked questions about University Hospital, Angers

How many clinical trials does University Hospital, Angers have on ClinicalTrials.gov?
University Hospital, Angers is listed as the lead sponsor on 469 clinical trials in ClinicalTrials.gov, 102 of which are currently active (recruiting, enrolling, or ongoing).
How many of University Hospital, Angers's trials are in Phase 3?
32 of University Hospital, Angers's trials are in Phase 3, spread across 21 active drug programs.
What therapeutic areas does University Hospital, Angers focus on?
University Hospital, Angers's most-studied conditions on ClinicalTrials.gov are Peripheral Artery Disease, Pseudoxanthoma Elasticum, Pulmonary Embolism, Peripheral Arterial Disease, Septic Shock.
When are University Hospital, Angers's next clinical trial readouts?
University Hospital, Angers has 10 upcoming primary-completion readouts tracked here; the soonest is “Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR”, expected around 2025-07.